SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-077706
Filing Date
2022-07-06
Accepted
2022-07-06 16:16:42
Documents
12
Period of Report
2022-07-06
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2220470d1_8k.htm   iXBRL 8-K 26667
  Complete submission text file 0001104659-22-077706.txt   199874

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nbrv-20220706.xsd EX-101.SCH 3030
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE nbrv-20220706_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nbrv-20220706_pre.xml EX-101.PRE 22593
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2220470d1_8k_htm.xml XML 3636
Mailing Address 414 COMMERCE DRIVE STE 120 FORT WASHINGTON PA 19034
Business Address 25-28 NORTH WALL QUAY DUBLIN L2 D01 H104 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 221068908
SIC: 2834 Pharmaceutical Preparations